Rapid Review Endocrine Flashcards
(99 cards)
Most common cause hypothyroidism
Hashimotos
Lab findings in Hashimotos
High TSH, low T4, anti-TPO ab, antimicrosomal ab
Exopthalmos, pretibial myxedema, decreased TSH, thyroid bruits
Graves
Most common cause Cushing’s syndrome
Iatrogenic corticosteroid administration
2nd: Cushing’s disease
Pt presents w/ signs hypocalcemia, high P, low PTH
Hypoparathyroidism
Stones, bones, groans, psychiatric overtones
S/S hypercalcemia
Pt c/o HA, weakness, polyuria; exam: HTN, tetany; Labs: hyperNa, hypoK, metabolic alkalosis
Primary hyperaldosteronism (due to Conn’s syndrome of bilateral adrenal hyperplasia)
Pt presents with tachycardia, wild BP swings, HA, diaphoresis, altered mental state, sense of panic
Pheochromocytoma
First in Tx of pheochromocytoma
Alpha antagonist: phentolamine or phenoxybenzamine
Pt w. Hx lithium use presents with copious amounts of dilute urin
Nephrogenic DI
Tx central DI
DDVAP and free water restriction
Postop pt with significant pain presents with hyponatremia and normal volume status
SIADH due to stress
Antidiabetic agent associated with lactic acidosis
Metformin
Pt presents with weakness, N/V, weight loss, new skin pigmentation. Labs show hyponatremia and hyperkalemia. Tx
Primary adrenal insufficiency- Addision’s
Tx: glucocorticoids, mineralocorticoids, IVF
Goal HgA1c for DM
<7.0
Beta blockers CI in DM
Mask hypoglycemia Sx
HLA association with DM I
HLA DR 3,4,DQ
4 ways to dx DM
- Random plasma glc >=200 with sx DM
- FPG>=126 on 2 occasions
- Plasma glc >=200 after 74 g OGT
- HgA1c >=6.5^
Mechanism biguanides
Adverse effects
METFORMIN
Dec hepatic gluconeogenesis, inc insulin activity, reduce LDL and raise HDL
GI, lactic acidosis, dec b12 absorption,
CI Renal and liver insufficiency
Sulfonylureas
Mechanism
Adverse effects
Glyburide, glimepiride, glipizide
Stimulate insulin release, reduce glucagon, inc insulin binding on tissue receptors
Adverse: hypoglycemia
CI: renal and hepatic insufficiency due to in risk hypoglycemia
Thiazolidinediones
Mechanism
Adverse
“Glitazones”
Increase tissue uptake of glc, dec gluconeogenesis
Adverse: weight gain, fluid retention (CI CHF), inc LDL, rare liver toxicity
Oral hypoglycemic associated with increased risk MI
Rosiglitazone
DPP IV inhibitors
Mechanism
Adverse effects
“Gliptin”
Inhibits degradation of incretin–>dec glucagon, inc insulin, delays gastric emptying
Adverse: diarrhea, constipation, edema
Incretin mimetics
Mechanism
Adverse
Exenatide, liraglutide
Agonizes GLP 1 receptor- same as DPP IV inhibitors
Adverse: mild weight loss, n, hypoglycemia, GI, risk pancreatitis
SC injection!!